Abstract |
Fulvestrant is a novel endocrine therapy for breast cancer that exerts both anti-estrogenic and down-regulatory effects by binding to and degrading estrogen receptors (ERs). In the present study, the safety and effectiveness of 500 mg fulvestrant in 69 patients with advanced, recurrent, ER-positive postmenopausal breast cancer were investigated retrospectively. Outcomes were favorable for fulvestrant. The objective response rate was 24.6%, the clinical benefit rate was 49.2%, the median progression-free survival (PFS) was 203 days, and the median overall survival was 794 days. PFS tended to be longer in patients without a history of previous treatment or visceral metastasis. The main adverse events included injection site reactions and hot flushes; however, the majority of these events were mild to moderate. The present findings suggest that, among Japanese patients with advanced, recurrent, ER-positive postmenopausal breast cancer, 500 mg fulvestrant is effective and safe in those without metastasis and a minimal history of receipt of previous treatment regimens.
|
Authors | Chiyomi Egawa, Masatsugu Okishiro, Yuichi Takatsuka |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 42
Issue 7
Pg. 811-5
(Jul 2015)
ISSN: 0385-0684 [Print] Japan |
PMID | 26197741
(Publication Type: Journal Article)
|
Chemical References |
- Estrogen Antagonists
- Receptors, Estrogen
- Fulvestrant
- Estradiol
|
Topics |
- Aged
- Aged, 80 and over
- Asian People
- Breast Neoplasms
(chemistry, drug therapy)
- Down-Regulation
- Estradiol
(adverse effects, analogs & derivatives, therapeutic use)
- Estrogen Antagonists
(adverse effects, therapeutic use)
- Female
- Fulvestrant
- Humans
- Middle Aged
- Postmenopause
- Receptors, Estrogen
(analysis, antagonists & inhibitors)
- Retrospective Studies
- Treatment Outcome
|